Aficamten + Placebo

Phase 3Active

1 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Conditions

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Trial Timeline

Aug 30, 2023 → Sep 1, 2026

NCT ID

NCT06081894

About Aficamten + Placebo

Aficamten + Placebo is a phase 3 stage product being developed by Sanofi for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy. The current trial status is active. This product is registered under clinical trial identifier NCT06081894. Target conditions include Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy.

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy were approved

Approved (3) Terminated (4) Active (9)

❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄rabeprazole sodium + PlaceboEisaiPhase 3

🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

🔄Pasireotide + OctreotideNovartisPhase 3

✅valsartanNovartisApproved

🔄Apixaban + Standard of carePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06081894	Phase 3	Active	Aug 30, 2023	Sep 1, 2026	Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Competing Products

20 competing products in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

See all competitors

Product	Company	Stage	Hype Score
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	32
ISV-305	Sun Pharmaceutical	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	35
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	32
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	40
DFV890 + Placebo	Novartis	Phase 2	35
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	35
Pasireotide + Octreotide	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 2	35
valsartan	Novartis	Approved	43
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Epoetin biosimilar	Pfizer	Pre-clinical	26
Apixaban + Standard of care	Pfizer	Phase 3	40
Azithromycin plus chloroquine	Pfizer	Phase 3	32
Mavacamten	Bristol Myers Squibb	Approved	50
Vandetanib 300 mg	Sanofi	Pre-clinical	26
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	47
Rivaroxaban + Placebo	Bayer	Phase 3	37
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	40